Novartis AG (NVSEF)
| Market Cap | 234.72B |
| Revenue (ttm) | 55.19B |
| Net Income (ttm) | 13.65B |
| Shares Out | n/a |
| EPS (ttm) | 6.85 |
| PE Ratio | 17.19 |
| Forward PE | 14.21 |
| Dividend | 3.97 (3.44%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 592 |
| Average Volume | 44,807 |
| Open | 118.50 |
| Previous Close | 115.50 |
| Day's Range | 115.50 - 118.50 |
| 52-Week Range | 94.70 - 126.34 |
| Beta | 0.55 |
| RSI | 47.96 |
| Earnings Date | Jul 17, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsNews
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
Novartis AG (NYSE: NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously trea...
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated ...
Roche, Novartis due to meet Swiss govt. amid Trump’s tariff threats: Reuters
Swiss government to meet pharma firms to discuss US tariffs
The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on it...
Novartis succeeds in late-stage Sjögren's disease trials
Rheinmetall, rsted, Novartis: Global Stocks in Focus
Novartis AG Announces Positive Phase III Trial Results for Ianalumab in Sjögren's Disease | ...
Novartis AG Announces Positive Phase III Trial Results for Ianalumab in Sjögren's Disease | NVS stock news
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients ...
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease | NVS Stock News
Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease
The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with Sjoegren's disease.
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's dis...
Swiss Government Engages Roche and Novartis on U.S. Tariff Impact
Swiss Government Engages Roche and Novartis on U.S. Tariff Impact
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal
Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech company.
Novartis weighs deal for biotech Avidity Biosciences, FT reports
Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic car...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in ...